A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
Hoffmann-La Roche
Monte Rosa Therapeutics, Inc
Duke University
AstraZeneca
Sapience Therapeutics
Poseida Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
University of Maryland, Baltimore
Dana-Farber Cancer Institute
Medstar Health Research Institute
Fred Hutchinson Cancer Center
Swiss Cancer Institute
Complement Theory Inc.
City of Hope Medical Center
University of Southern California
UNICANCER
BicycleTx Limited
AstraZeneca
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Pfizer
Vanderbilt-Ingram Cancer Center
University of Colorado, Denver
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
University of Alabama at Birmingham
University College, London
Memorial Sloan Kettering Cancer Center
Klus Pharma Inc.
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Memorial Sloan Kettering Cancer Center
Cybrexa Therapeutics
Carisma Therapeutics Inc
University of Toronto
Region Örebro County
Actuate Therapeutics Inc.
Dana-Farber Cancer Institute
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc